“If the two III trials are positive, we will submit a new drug to FDA in 2019,” the vTv Therapeutics chief executive, Stephen Holcomb, in the early January interview on the Alzheimer’s drug azeliragon, adding: “azeliragon has gained the speed of FDA. The passage, the approval process will be accelerated. ”
It is precisely because the failure rate of new drug development for Alzheimer’s disease is high enough that azeliragon attracts enough attention. But the greater the hope, the greater the disappointment. When azeliragon came to a III clinic in April 10th, the stock price of vTv Therapeutics fell hard enough, and the price of 78% closed at $0.71.
Similar tragic incidents have not occurred in pharmaceutical giants. In November 23, 2016, third big solanezumab III EXPEDITION3 studies failed again, and Lilly shares ended down 10.5%.
Altz sea disease is the “live burial site” of new drug research and development. If you want to have a deeper understanding of this, look at a chart from the new medicine library of medicine magic cube (click on the picture). Only a target of A beta has 8 projects failed or aborted, not to mention AChE, BACE… This failure rate can be quite shocking.
The fiasco in this field could not even be seen by FDA, so a new guide was released in February 15, 2018, “Early Alzheimer ‘s Disease: Developing Drugs for Treatment”. (see: the latest Alzheimer’s disease drug development guide for FDA).
Under the new guide, if a company can find a new drug to fight or reverse Alzheimer’s disease, it is undoubtedly a gold mine, and we pray that the day will come soon.